SkinBioTherapeutics plc SkinBiotix® technology human study commenced

Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented:

“I am delighted that we now have all three aspects of our human study scheduled. Data from the two initial tests is expected in October 2018, and data from the third, larger test, is expected in Q4 2018 and Q1 2019. We hope that these results will provide additional proof of the SkinBiotix® technology’s efficacy and enable us to continue to pursue commercial discussions”.

SkinBioTherapeutics plc (LON: SBTX), a life science company focused on skin health, confirmed that it has commenced its human study being carried out on its SkinBiotix® technology.

There are three elements to the human study: the first, already underway, is to assess skin irritancy; the second, due to commence on 20 September 2018, is to assess moisturisation potential; and the third is to assess the technology’s impact on the barrier function. This third element of the study, for which the Company has now received final ethics approval, has been rescheduled to commence in November due to capacity issues within the clinical research organisation.

Study one is a skin irritancy test using different concentrations of SkinBiotix® in the cream formulation. Five different concentrations of the technology will be compared with the base formulation (i.e. containing no SkinBiotix®) and an existing marketed dermatological cream. Thirty volunteers will be assessed for irritancy at various time points up to 72 hours. The results are expected in October 2018.

Study two is an evaluation of the moisturisation potential of the SkinBiotix® cream formulation compared to the base formulation. The study will assess 20 participants, with approximately a 12 hour treatment period for each volunteer. The results are expected in October 2018.

Study three is a test to determine whether the positive impact of the technology on the skin’s barrier function, which has been demonstrated in laboratory studies, is replicated in human volunteers. The Company has now received final ethics approval for the commencement of this study. The study will be conducted with 120 female volunteers with self-assessed ‘dry skin’. The first 20 volunteers will be treated in November 2018 with the remaining 100 volunteers treated in January 2019. Data on the first 20 volunteers is expected to be available in December 2018 with the full read out on all 120 volunteers available during Q1 2019.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    SkinBiotherapeutics Plc

    More articles like this

    SkinBiotherapeutics Plc

    Why we should all be eating a microbiome diet

    First, let’s briefly talk about the microbiome. The gut microbiome refers to the trillions of bacteria that live within our gastrointestinal tracts. If you were to collectively bunch them all up into a ball, it would

    SkinBiotherapeutics Plc

    Microbiome-based therapy for eczema: On the horizon?

    Results of pre-clinical and early clinical trials conducted by investigators at the National Institutes of Health showing the effectiveness of using bacteria to treat eczema are paving the way for further study into the potential for

    SkinBiotherapeutics Plc

    SkinBioTherapeutics plc achieved significant manufacturing scale up

    Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented: “The progress we’ve made so far in manufacturing and freeze-drying the lysate is very encouraging. The current formulation is undergoing extended stability studies in preparation for the human study.”

    SkinBiotherapeutics Plc

    Protect your skin microbiome

    Like your gut, your skin also has a complex system of bacteria and fungi living on its surface. “It sounds weird and scary, but it’s actually good for you,” says Sarvenaz Zand, M.D., a dermatologist based

    SkinBiotherapeutics Plc

    What Is Dyshidrotic Eczema, Exactly?

    If you have found your way to this story, then there is a good chance you’re feeling the itch. Dyshidrotic Eczema is a common form of eczema that can crop up as crazy itchy blisters on

    SkinBiotherapeutics Plc

    Bacteria on your skin could speed healing

    Microbes on the surface of the skin help the immune system to respond to injury and heal wounds. Immunity research have historically focused on the response to pathogens and inflammation, and so relatively little is known

    SkinBiotherapeutics Plc

    Can you really use probiotics to fight acne?

    If you’ve ever had a breakout, you’ve likely tried to dry those suckers up with bacteria-killing washes and spot treatments. You know, because conventional wisdom (and lots of research) has shown that zits, particularly the big painful

    SkinBiotherapeutics Plc

    SkinBiotherapeutics is harnessing the power of Microbiome

    SkinBioTherapeutics (LON:SBTX) CEO Dr Cath O’Neill worked in the field of gastroenterology, investigating the effect of probiotics on the intestinal barrier function, an area which had already seen significant commercial success through health foods and yoghurt

    SkinBiotherapeutics Plc

    Skin Microbiome: Why You want Bacteria On Your Skin

    The gut gets the majority of the attention when we talk about the microbiome (even though your mouth has a vast microbiome as well!). The digestive system is home to trillions of organisms that can affect the body,